ACAD- Acadia Pharmaceuticals Inc.

Name: Acadia Pharmaceuticals Inc. Insider Trading Data
Creator: U.S. Securities and Exchange Commission
License: https://www.sec.gov/privacy#accessibility

Acadia Pharmaceuticals Inc. (ACAD) has 12 insiders with recent SEC Form 4 filings, including 0 buys and 12 sells. ACAD is classified in the Biotechnology industry within the Health Care sector.

Insider Ownership

Role	Insider	Shares	Value	30d
CFO	Schneyer Mark C.	66.1K	$1.50M	-3,506
Dir	Harrigan Edmund	35.0K	$792.3K	-
Other	Kihara James	29.1K	$658.6K	-1,332
10%	Baker Bros. Advisors LP	27.6K	$623.7K	-
Dir	Garofalo Elizabeth A.	25.4K	$573.9K	-

Activity

Buys and sells only

Transactions

10 filings · page 4

Date	Insider	Role	Type	Shares	Price	Value	Chg%	3M	12M
Aug 19, 2024	Schneyer Mark C.59	EVP, Chief Financial Officer	Sell	9,733	$15.28	$148,720.24	-18.2%	+8.1%	+58.4%
Jun 10, 2024	Schneyer Mark C.59	EVP, Chief Financial Officer	Sale+OE	975	$14.79	$14,420.25	-2.7%	+6.0%	+49.2%
May 2, 2024	Schneyer Mark C.59	EVP, Chief Financial Officer	Sale+OE	3,503	$16.94	$59,340.82	-9.9%	+11.4%	-12.7%
May 2, 2024	Teehan Brendan62	EVP, COO, Head Of Commercial	Sale+OE	3,477	$16.94	$58,900.38	-7.6%	+11.4%	-12.7%
May 2, 2024	Kihara James62	Principal Accounting Officer	Sale+OE	1,326	$16.94	$22,462.44	-8.4%	+11.4%	-12.7%
May 2, 2024	Davis Stephen68	CEO	Sale+OE	11,427	$16.94	$193,573.38	-6.9%	+11.4%	-12.7%
Apr 8, 2024	Davis Stephen68	CEO	Sale+OE	26,574	$17.87	$474,877.38	-8.0%	-8.3%	-20.8%
Apr 8, 2024	Teehan Brendan62	EVP, COO, Head Of Commercial	Sale+OE	2,568	$17.87	$45,890.16	-6.2%	-8.3%	-20.8%
Apr 8, 2024	Schneyer Mark C.59	EVP, Chief Financial Officer	Sale+OE	2,716	$17.87	$48,534.92	-8.6%	-8.3%	-20.8%
Apr 8, 2024	Kihara James62	Principal Accounting Officer	Sale+OE	1,790	$17.87	$31,987.30	-6.2%	-8.3%	-20.8%

← PrevPage 4Next →

Insider	Role	Shares	Value	Buys	Sells

Date	Ticker	Insider	Role	Type	Shares	Price	Value	Chg%	SEC